Future perspectives on the fibrinolytic therapy of intracerebral hemorrhages

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2011, Pages 150-156

  Thiex, Ruth ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Edema formation; Excitotoxicity; Fibrinolysis; Inflammation; Intracerebral hemorrhage; Plasminogen activator

Indexed keywords

ALTEPLASE; DESMOTEPLASE; DIZOCILPINE; NEUROPROTECTIVE AGENT; PLACEBO; UROKINASE;

ARTICLE; BRAIN EDEMA; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INJURY; DRUG DOSE ESCALATION; DRUG EFFICACY; EXCITOTOXICITY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; NEUROTOXICITY; NONHUMAN; PUNCTURE;

EID: 79959313907     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152411796011367     Document Type: Article

References (53)

1. Broderick, J.; Connolly, S.; Feldmann, E.; Hanley, D.; Kase, C.; Krieger, D.; Mayberg, M.; Morgenstern, L.; Ogilvy, C.S.; Vespa, P.; Zuccarello, M. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Circulation, 2007, 116(16), 391-413.
2. Broderick, J.P.; Brott, T.; Tomsick, T.; Miller, R.; Huster, G. Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J. Neurosurg., 1993, 78(2), 188-191.
3. Anderson, C.S.; Chakera, T.M.; Stewart-Wynne, E.G.; Jamrozik, K.D. Spectrum of primary intracerebral haemorrhage in Perth, Western Australia, 1989-90: incidence and outcome. J. Neurol. Neurosurg. Psychiatry., 1994, 57(8), 936-940.
4. Weimar, C.; Weber, C.; Wagner, M.; Busse, O.; Haberl, R.L.; Lauterbach, K.W.; Diener, H.C. Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in Germany. Cerebrovasc. Dis., 2003, 15(1-2), 29-36.
5. Christensen, M.C.; Previgliano, I.; Capparelli, F.J.; Lerman, D.; Lee, W.C.; Wainsztein, N.A. Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina. Acta. Neurol. Scand., 2009, 119(4), 246-253.
6. Yoneda, Y.; Okuda, S.; Hamada, R.; Toyota, A.; Gotoh, J.; Watanabe, M.; Okada, Y.; Ikeda, K.; Ibayashi, S.; Hasegawa, Y.Hospital cost of ischemic stroke and intracerebral hemorrhage in Japanese stroke centers. Health. Policy., 2005, 73(2), 202-211.
7. Ferro, J.M. Update on intracerebral haemorrhage. J. Neurol., 2006, 253(8), 985-999.
8. Chen, S.T.; Chen, S.D.; Hsy, C.Y.; Hogan, E.L. Progression of hypertensive intracerebral hemorrhage. Neurology, 1989, 39(11), 1514-1518.
9. Fujii, Y.; Tanaka, R.; Takeuchi, S.; Koike, T.; Minakawa, T.; Sasaki, O. Hematoma enlargement in spontaneous intracerebral hemorrhage. J. Neurosurg., 1994, 80(1), 51-57.
10. Labovitz, D.L. and Sacco, R.L. Intracerebral hemorrhage: update. Curr. Opin. Neurol., 2001, 14(1), 103-8.
11. Silva, Y.; Leira, R.; Tejada, J.; Lainez, J.M.; Castillo, J.; Davalos, A. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke, 2005, 36(1), 86-91.
12. Hemphill, J.C., 3rd; Bonovich, D.C.; Besmertis, L.; Manley, G.T.; Johnston, S.C. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke, 2001, 32(4), 891-897.
13. Monroe, D.M.; Hoffman, M.; Oliver, J.A.; Roberts, H.R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br. J. Haematol., 1997, 99(3), 542-547.
14. Mayer, S.A.; Brun, N.C.; Begtrup, K.; Broderick, J.; Davis, S.; Diringer, M.N.; Skolnick, B.E.; Steiner, T. Recombinant activated factor VII for acute intracerebral hemorrhage. N. Engl. J. Med., 2005, 352(8), 777-85.
15. Brown, D.L. and Morgenstern, L.B. Stopping the bleeding in intracerebral hemorrhage. N Engl. J. Med., 2005, 352(8), 828-830.
16. Mayer, S.A.; Brun, N.C.; Begtrup, K.; Broderick, J.; Davis, S.; Diringer, M.N.; Skolnick, B.E.; Steiner, T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N. Engl. J. Med., 2008, 358(20), 2127-2137.
17. Mayer, S.A.; Davis, S.M.; Skolnick, B.E.; Brun, N.C.; Begtrup, K.; Broderick, J.P.; Diringer, M.N.; Steiner, T. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII? Stroke. 2009, 40(3), 833-840.
18. Ropper, A.H. and King, R.B. Intracranial pressure monitoring in comatose patients with cerebral hemorrhage. Arch. Neurol., 1984, 41(7), 725-728.
19. Wagner, K.R.; Xi, G.; Hua, Y.; Kleinholz, M.; de Courten-Myers, G.M.; Myers, R.E.; Broderick, J.P.; Brott, T.G. Lobar intracerebral hemorrhage model in pigs: rapid edema development in perihematomal white matter. Stroke, 1996, 27(3), 490-497.
20. Alvarez-Sabin, J.; Delgado, P.; Abilleira, S.; Molina, C.A.; Arenillas, J.; Ribo, M.; Santamarina, E.; Quintana, M.; Monasterio, J.; Montaner, J. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke, 2004, 35(6), 1316-1322.
21. Xi, G.; Keep, R.F.; Hoff, J.T. Pathophysiology of brain edema formation. Neurosurg. Clin. N. Am., 2002, 13(3), 371-383.
22. Mendelow, A.D.; Gregson, B.A.; Fernandes, H.M.; Murray, G.D.; Teasdale, G.M.; Hope, D.T.; Karimi, A.; Shaw, M.D.; Barer, D. H. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet, 2005, 365(9457), 387-97.
23. Qureshi, A.I.; Tuhrim, S.; Broderick, J.P.; Batjer, H.H.; Hondo, H.; Hanley, D.F. Spontaneous intracerebral hemorrhage. N. Engl. J. Med., 2001, 344(19), 1450-1460.
24. Zuccarello, M.; Brott, T.; Derex, L.; Kothari, R.; Sauerbeck, L.; Tew, J.; Van Loveren, H.; Yeh, H.S.; Tomsick, T.; Pancioli, A.; Khoury, J.; Broderick, J. Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study. Stroke, 1999, 30(9), 1833-1839.
25. Auer, L.M.; Deinsberger, W.; Niederkorn, K.; Gell, G.; Kleinert, R.; Schneider, G.; Holzer, P.; Bone, G.; Mokry, M.; Korner, E. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study. J. Neurosurg., 1989, 70(4), 530-535.
26. Thiex, R.; Rohde, V.; Rohde, I.; Mayfrank, L.; Zeki, Z.; Thron, A.; Gilsbach, J.M.; Uhl, E. Frame-based and frameless stereotactic hematoma puncture and subsequent fibrinolytic therapy for the treatment of spontaneous intracerebral hemorrhage. J. Neurol., 2004, 251(12), 1443-1450.
27. Teernstra, O.P.; Evers, S.M.; Lodder, J.; Leffers, P.; Franke, C.L.; Blaauw, G. Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: a multicenter randomized controlled trial (SICHPA). Stroke, 2003, 34(4), 968-974.
28. Wagner, K.R.; Xi, G.; Hua, Y.; Zuccarello, M.; de Courten-Myers, G.M.; Broderick, J.P.; Brott, T.G. Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection. J. Neurosurg., 1999, 90(3), 491-498.
29. Lippitz, B.E.; Mayfrank, L.; Spetzger, U.; Warnke, J.P.; Bertalanffy, H.; Gilsbach, J.M. Lysis of basal ganglia haematoma with recombinant tissue plasminogen activator (rtPA) after stereotactic aspiration: initial results. Acta. Neurochir. (Wien)., 1994, 127(3-4), 157-160.
30. Schaller, C.; Rohde, V.; Meyer, B.; Hassler, W. Stereotactic puncture and lysis of spontaneous intracerebral hemorrhage using recombinant tissue-plasminogen activator. Neurosurgery, 1995, 36(2), 328-33; discussion 333-335.
31. Morgan, T.; Zuccarello, M.; Narayan, R.; Keyl, P.; Lane, K.; Hanley, D. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta. Neurochir. Suppl., 2008, 105, 147-151.
32. Elliott, J. and Smith, M. The acute management of intracerebral hemorrhage: a clinical review. Anesth. Analg., 2010, 110(5), 1419-1427.
33. Thiex, R.; Kuker, W.; Muller, H.D.; Rohde, I.; Schroder, J.M.; Gilsbach, J.M.; Rohde, V. The long-term effect of recombinant tissue-plasminogen-activator (rt-PA) on edema formation in a large-animal model of intracerebral hemorrhage. Neurol. Res., 2003, 25(3), 254-62.
34. Thiex, R.; Mayfrank, L.; Rohde, V.; Gilsbach, J.M.; Tsirka, S.A. The role of endogenous versus exogenous tPA on edema formation in murine ICH. Exp. Neurol., 2004, 189(1), 25-32.
35. Rogove, A.D. and Tsirka, S.E. Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr. Biol., 1998, 8(1), 19-25.
36. Rogove, A.D.; Siao, C.; Keyt, B.; Strickland, S.; Tsirka, S.E. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J. Cell. Sci., 1999, 112 (Pt 22), 4007-4016.
37. Wang, J.; Rogove, A.D.; Tsirka, A.E.; Tsirka, S. E. Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage. Ann. Neurol., 2003, 54(5), 655-664.
38. Lo, E.H.; Broderick, J.P.; Moskowitz, M.A. tPA and proteolysis in the neurovascular unit. Stroke, 2004, 35(2), 354-356.
39. Lo, E.H.; Wang, X.; Cuzner, M.L. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res., 2002, 69(1), 1-9.
40. Nicole, O.; Docagne, F.; Ali, C.; Margaill, I.; Carmeliet, P.; MacKenzie, E.T.; Vivien, D.; Buisson, A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptormediated signaling. Nat. Med., 2001, 7(1), 59-64.
41. Samson, A.L.; Nevin, S.T.; Croucher, D.; Niego, B.; Daniel, P.B.; Weiss, T.W.; Moreno, E.; Monard, D.; Lawrence, D.A.; Medcalf, R.L. Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J. Neurochem., 2008, 107(4), 1091-101.
42. Lopez-Atalaya, J.P.; Roussel, B.D.; Levrat, D.; Parcq, J.; Nicole, O.; Hommet, Y.; Benchenane, K.; Castel, H.; Leprince, J.; To Van, D.; Bureau, R.; Rault, S.; Vaudry, H.; Petersen, K.U.; Santos, J.S.; Ali, C.; Vivien, D. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J. Cereb. Blood. Flow. Metab., 2008, 28(6), 1212-1221.
43. Thiex, R.; Weis, J.; Krings, T.; Barreiro, S.; Yakisikli-Alemi, F.; Gilsbach, J.M.; Rohde, V. Addition of intravenous N-methyl-Daspartate receptor antagonists to local fibrinolytic therapy for the optimal treatment of experimental intracerebral hemorrhages. J. Neurosurg., 2007, 106(2), 314-320.
44. Olney, J.W.; Labruyere, J.; Price, M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 1989, 244(4910), 1360-1362.
45. Kratzschmar, J.; Haendler, B.; Langer, G.; Boidol, W.; Bringmann, P.; Alagon, A.; Donner, P.; Schleuning, W.D. The plasminoge activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene, 1991, 105(2), 229-237.
46. Liberatore, G.T.; Samson, A.; Bladin, C.; Schleuning, W.D.; Medcalf, R.L. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke, 2003, 34(2), 537-543.
47. Bringmann, P.; Gruber, D.; Liese, A.; Toschi, L.; Kratzchmar, J.; Schleuning, W.D.; Donner, P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J. Biol. Chem., 1995, 270(43), 25596-25603.
48. Reddrop, C.; Moldrich, R.X.; Beart, P.M.; Farso, M.; Liberatore, G.T.; Howells, D.W.; Petersen, K.U.; Schleuning, W.D.; Medcalf, R.L. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke, 2005, 36(6), 1241-1246.
49. Lopez-Atalaya, J.P.; Roussel, B.D.; Ali, C.; Maubert, E.; Petersen, K.U.; Berezowski, V.; Cecchelli, R.; Orset, C.; Vivien, D. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke, 2007, 38(3), 1036-1043.
50. Hacke, W.; Albers, G.; Al-Rawi, Y.; Bogousslavsky, J.; Davalos, A.; Eliasziw, M.; Fischer, M.; Furlan, A.; Kaste, M.; Lees, K.R.; Soehngen, M.; Warach, S. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke, 2005, 36(1), 66-73.
51. Furlan, A.J.; Eyding, D.; Albers, G.W.; Al-Rawi, Y.; Lees, K.R.; Rowley, H.A.; Sachara, C.; Soehngen, M.; Warach, S.; Hacke, W. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke, 2006, 37(5), 1227-1231.
52. Hacke, W.; Furlan, A.J.; Al-Rawi, Y.; Davalos, A.; Fiebach, J.B.; Gruber, F.; Kaste, M.; Lipka, L.J.; Pedraza, S.; Ringleb, P.A.; Rowley, H.A.; Schneider, D.; Schwamm, L.H.; Leal, J.S.; Sohngen, M.; Teal, P.A.; Wilhelm-Ogunbiyi, K.; Wintermark, M.; Warach, S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebocontrolled study. Lancet. Neurol., 2009, 8(2), 141-150.
53. Rohde, V.; Uzma, N.; Thiex, R.; Samadani, U. Management of delayed edema formation after fibrinolytic therapy for intracerebral hematomas: preliminary experimental data. Acta. Neurochir. Suppl., 2008, 105, 101-104.